Study details
Enrolling now
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Uniquity One (UNI)
NCT IDNCT06496620ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
171
Study length
about 2.2 years
Ages
40–75
Locations
101 sites in AL, AZ, CA +28
What this study is about
This trial is testing a treatment called solrikitug, along with a placebo, in people with COPD. The goal is to see if solrikitug is safe and well-tolerated.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Receive Biological: Solrikitug high dose
- 3.Receive Biological: Solrikitug low dose
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Change from baseline in blood eosinophil counts
Secondary: Change from baseline in FEV1 Adverse events (AEs) and serious adverse events (SAEs)
Body systems
Respiratory